Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROSSCHECK-001: CBX-250 in Relapsed or Refractory Myeloid Leukemias
NCT06994676Phase 1Recruiting
- Sponsor
- Crossbow Therapeutics
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Bispecific Antibodies, T-cell Engagers, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CBX-250 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 1 more, sponsored by Crossbow Therapeutics. Primary endpoint: Safety, tolerability, RP2D, or MTD if different, and dosing regimen of CBX-250 at 24 months. Started Jul 2025; status: recruiting.
02
Drugs
CBX-250
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06994676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994676.